Danoprevir

Drug Profile

Danoprevir

Alternative Names: ASC-08; ITMN-191; ITMN-B; R-7227; RG-7227; RO-5190591

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Array BioPharma; InterMune
  • Developer Ascletis; Roche
  • Class Antivirals; Carboxylic acids; Cyclopropanes; Isoindoles; Macrocyclic compounds; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hepatitis C

Most Recent Events

  • 27 Dec 2016 Preregistration for Hepatitis C (Combination therapy, Treatment-naive) in China (PO)
  • 27 Dec 2016 China FDA accepts NDA for danoprevir in Hepatitis C
  • 21 Jun 2016 Interim safety and efficacy data from a phase II EVEREST trial in Chronic hepatitis C released by Ascletis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top